Skip to main content
OpenTrials
Completed

NCT Number: NCT07493343

EUSOL vs. PDGF Dressing for Diabetic Foot Ulcers

Diabetic foot ulcers are a major cause of morbidity and amputation. This randomized controlled trial will compare the efficacy of a traditional antiseptic dressing (EUSOL) with a modern biologic dressing containing Platelet-Derived Growth Factor (PDGF) in promoting wound contraction. The study aims to determine if PDGF dressing leads to better healing outcomes in patients with Grade II Wagner diabetic foot ulcers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetic Wound Cardiovascular Diseases Diabetes Complications Diabetes Mellitus Diabetic Angiopathies Diabetic Foot Diabetic Neuropathies Endocrine System Diseases Foot Ulcer Leg Ulcer Skin Diseases Skin Ulcer Skin and Connective Tissue Diseases Vascular Diseases

Age range

30 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Services Institute of Medical Sciences

Lahore, Punjab Province, 54000, Pakistan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of diabetes mellitus.
  • Presence of a Grade II Wagner diabetic foot ulcer (penetrating to subcutaneous tissue, without involvement of tendon, bone, or joint).
  • Ulcer size less than 6 x 6 cm at baseline.

Exclusion criteria

  • Uncontrolled diabetes
  • Malnourished (BMI less than 20)
  • HB less than 10
  • ABPI less than 0.9
  • Immunosuppression therapy
  • Patients with malignancy or uncontrolled cardiopulmonary, neurological, or psychiatric disease.
  • Severe active infection

Treatment and study plan

EUSOL Dressing

Procedure

Daily dressing with freshly prepared Edinburgh University Solution of Lime (EUSOL) applied to the ulcer after standard debridement and cleansing.

Platelet-Derived Growth Factor (PDGF) Dressing

Procedure

PDGF-based topical preparation applied to the ulcer surface every fourth day, covered by a secondary dressing. Interim dressing changes used normal saline only.

Primary outcomes

  1. Proportion of patients achieving wound contraction.

    Time frame: 4 weeks

    Wound healing will be defined as the achievement of at least a 50% reduction in ulcer area from baseline after four weeks of treatment. Ulcer area will be calculated as maximum length multiplied by maximum width.

Sponsors and collaborators

Lead sponsor

Services Hospital, Lahore

Other Gov

Collaborators

  • Services Institute of Medical Sciences, Pakistan

Registry information

Official study title

Comparison of EUSOL Dressing Versus Platelet Derived Growth Factor Dressing in Wound Contraction of Grade II Wagner Diabetic Foot Ulcers: A Randomized Controlled Trial

Important dates

Study start
2020
Primary completion
2025
Study completion
2026
First posted
Mar 25, 2026
Registry last updated
Mar 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.